Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

The Cardiovascular and Renal Drugs Advisory Committee will meet on ... UPDATED: Thursday, Jan. 2 at 1:45 p.m. ET Shortly before the new year, Merck & Co. scored an approval for its potential ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...